nutrition for glp 1 Introducing the GLP-1 Balanced Plant-Based Plate 🥗 GLP-1 therapy changes appetite, not nutritional needs. When patients eat less, nutritional quality becomes even more important. Smaller portions mean fewer opportunities to support protein GLP-ONE Support Gut Health Booster

In short, it may encourage your body to use stored fat more efficiently

Fast check-in and very clear instructions about repeat visits

These typically improve over 48 weeks but may require slower dose titration or, in some cases, discontinuation of treatment

In complex chronic conditions like Long COVID, the elegant and highly regulated machinery of cellular energy production is frequently thrown into absolute chaos

Glucagon-Like-Peptide 1 (GLP-1)

Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans